Clinical Trials - March 23, 2016
AZ reports results from the Brilinta SOCRATES trial
AstraZeneca announces results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique(ticagrelor) 90mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA). The primary efficacy endpoint of time to first occurrence of any event from the composite of stroke (ischaemic or haemorrhagic), myocardial […]
Acquisition - March 21, 2016
AZ acquires all rights to Orexo’s OX-CLI
AstraZeneca has decided to acquire all rights to Orexo’s leukotriene C4 synthase inhibitor program (OX-CLI project) for MUSD 5. AstraZeneca established a collaboration with Orexo AB for OX-CLI in 2013 and maintained an option to acquire all rights in the program. As the program has advanced into pre-clinical development with an identified development compound (candidate drug), […]
Collaboration - March 18, 2016
Lipigon in collaboration with AstraZeneca
The spin-off company, and Umeå Biotech Incubator project, Lipigon Pharmaceuticals and AstraZeneca have entered a research collaboration to develop a high throughput assay for the identification of molecules against elevated blood lipids. Lipoprotein lipase (LPL) is a promising target for development of new medicines for dyslipidemia and other cardiometabolic risk markers. Recent evidence from genetic- […]
Acquisition - March 1, 2016
AZ in agreement with ProStrakan
AstraZeneca has entered into an agreement with ProStrakan Group, a subsidiary of Kyowa Hakko Kirin Co. Ltd., for the rights to Moventig (naloxegol) in the European Union (EU), Iceland, Norway, Switzerland and Liechtenstein. Moventig is the first once-daily, oral peripherally-acting mu-opioid receptor antagonist (PAMORA) approved in Europe for the treatment of opioid-induced constipation (OIC) in […]
Agreement - February 29, 2016
AstraZeneca in licensing agreement with China Medical System Holdings
AstraZeneca has entered into a licensing agreement with China Medical System Holdings Ltd (CMS) for the commercialisation rights in China to its calcium channel blocker, Plendil (felodipine). Plendil was first approved in China in 1995 for the treatment of hypertension or high blood pressure and in 2015 achieved Product Sales of $189 million. Under the terms […]
Drug Development Pharma - February 23, 2016
AZ’s Brilique approved in EU for extended treatment of patients with history of heart attack
AstraZeneca has announced that the European Commission has granted marketing authorisation for Brilique (ticagrelor) at a new 60mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event. Treatment may be started as continuation therapy after an initial […]
